Cas:135072-32-1 Ethyl 4-Benzyl-2-morpholinecarboxylate manufacturer & supplier

Chemical Name:Ethyl 4-Benzyl-2-morpholinecarboxylate

CAS.NO:135072-32-1

Synonyms:Ethyl 4-benzylmorpholine-2-carboxylate;Ethyl4-benzylmorpholine-2-carboxylate

Molecular Formula:C₁₄H₁₉NO₃

Molecular Weight:249.30600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:330.328ºC at 760 mmHg

Density:1.128g/cm3

Index of Refraction:1.531

PSA:38.77000

Exact Mass:249.13600

LogP:1.38840

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like Ethyl 4-benzylmorpholine-2-carboxylate chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Ethyl4-benzylmorpholine-2-carboxylate physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Ethyl4-benzylmorpholine-2-carboxylate Use and application,Ethyl 4-benzylmorpholine-2-carboxylate technical grade,usp/ep/jp grade.

Related News: but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process. diethyl 2-((4-carbamoyl-1H-imidazol-5-yl)diazenyl)-2-nitromalonate manufacturers Over the duration of this study, investigators observed a 4.2% reduction in annualised absolute risk of cardiovascular death or heart failure hospitalisations compared to placebo. 3,4-dimethoxy-5-(2-trimethylsilylethynyl)benzoic acid suppliers but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process. 6-chloro-1-(2-(4-(4-hydroxybutyl)piperidin-1-yl)-2-oxoethyl)thiazolo[5,4-b]pyridin-2(1H)-one vendor & factory “The Delta variant is clearly circulating, and it’s more contagious, and it seems to be causing more disease,” said ACIP member Katherine Poehling, M.D., an epidemiologist at Wake Forest School of Medicine. ,but are not expected to recover the costs of developing and marketing a treatment drug.” Due to the high costs and low demands of the drug product, it is important to efficiently use API supply during the formulation process.